Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/antiangiogenic-therapies-in-colorectal-cancer-9Z5S7dpO29
References (30)
-
B. Giantonio, P. Catalano, N. Meropol, P. O'dwyer, E. Mitchell, S. Alberts, M. Schwartz, A. Benson (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 12
-
G. Naumov, L. Akslen, J. Folkman (2006)
Role of Angiogenesis in Human Tumor Dormancy: Animal Models of the Angiogenic SwitchCell Cycle, 5
-
A. Ryerson, C. Eheman, S. Altekruse, J. Ward, A. Jemal, Recinda Sherman, S. Henley, D. Holtzman, Andrew Lake, A. Noone, Robert Anderson, Jiemin Ma, Kathleen Ly, K. Cronin, L. Penberthy, B. Kohler (2016)
Annual Report to the Nation on the Status of Cancer, 1975‐2012, featuring the increasing incidence of liver cancerCancer, 122
-
G. Folprecht, C. Pericay, Marisa Saunders, Anne Thomas, R. Lopez, J. Roh, V. Chistyakov, T. Höhler, Jun Kim, R. Hofheinz, S. Ackland, S. Ackland, D. Swinson, M. Kopp, D. Udovitsa, M. Hall, T. Iveson, Arndt Vogel, J. Zalcberg (2016)
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.Annals of oncology : official journal of the European Society for Medical Oncology, 27 7
-
R. Siegel, K. Miller, A. Jemal (2016)
Cancer statistics, 2016CA: A Cancer Journal for Clinicians, 66
-
C. Allegra, G. Yothers, M. O’connell, S. Sharif, N. Petrelli, L. Colangelo, J. Atkins, T. Seay, L. Fehrenbacher, R. Goldberg, S. O'reilly, L. Chu, C. Azar, Samia Lopa, N. Wolmark (2011)
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 1
-
D. Lambrechts, H. Lenz, S. Haas, P. Carmeliet, S. Scherer (2013)
Markers of response for the antiangiogenic agent bevacizumab.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 9
-
C. Fuchs, J. Marshall, E. Mitchell, R. Wierzbicki, V. Ganju, M. Jeffery, J. Schulz, D. Richards, Raoudha Soufi-Mahjoubi, Benjamin Wang, J. Barrueco (2007)
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 30
-
T. Botrel, L. Clark, L. Paladini, O. Clark (2016)
Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysisBMC Cancer, 16
-
S. Mocellin, Z. Baretta, Marta Figuls, I. Solá, M. Martín-Richard, Sara Hallum, X. Cosp (2017)
Second-line systemic therapy for metastatic colorectal cancer.The Cochrane database of systematic reviews, 1
-
R. Kerr, S. Love, E. Segelov, E. Johnstone, Beverly Falcón, P. Hewett, A. Weaver, D. Church, C. Scudder, S. Pearson, P. Julier, F. Pezzella, I. Tomlinson, E. Domingo, D. Kerr (2016)
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.The Lancet. Oncology, 17 11
-
L. Saltz, S. Clarke, E. Díaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T.S. Yang, F. Rivera, F. Couture, F. Sirzén, J. Cassidy (2023)
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 41
-
R. Dienstmann, L. Vermeulen, J. Guinney, S. Kopetz, S. Tejpar, J. Tabernero (2017)
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancerNature Reviews Cancer, 17
-
A. Grothey, E. Cutsem, A. Sobrero, S. Siena, A. Falcone, M. Ychou, Y. Humblet, O. Bouché, L. Mineur, C. Barone, A. Adenis, J. Tabernero, T. Yoshino, H. Lenz, R. Goldberg, D. Sargent, F. Cihon, L. Cupit, A. Wagner, D. Laurent (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 381
-
F. Kabbinavar, J. Schulz, M. Mccleod, T. Patel, J. Hamm, J. Hecht, R. Mass, B. Perrou, B. Nelson, W. Novotny (2005)
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 16
-
A. Figueredo, M. Charette, J. Maroun, M. Brouwers, L. Zuraw (2004)
Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 16
-
RL Siegel, KD Miller, A Jemal (2016)
Cancer statisticsCA Cancer J Clin, 66
-
G. Masi, E. Vasile, F. Loupakis, S. Cupini, L. Fornaro, G. Baldi, L. Salvatore, C. Cremolini, I. Stasi, I. Brunetti, M. Fabbri, M. Puglisi, P. Trenta, C. Granetto, S. Chiara, L. Fioretto, G. Allegrini, L. Crinò, M. Andreuccetti, A. Falcone (2011)
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.Journal of the National Cancer Institute, 103 1
-
J. Tabernero, T. Yoshino, A. Cohn, R. Obermannova, G. Bodoky, R. García-Carbonero, T. Ciuleanu, D. Portnoy, E. Cutsem, A. Grothey, J. Prausová, P. García-Alfonso, K. Yamazaki, P. Clingan, S. Lonardi, Tae Kim, L. Simms, Shao-chun Chang, F. Nasroulah (2015)
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.The Lancet. Oncology, 16 5
-
G. Masi, L. Salvatore, L. Boni, F. Loupakis, C. Cremolini, L. Fornaro, M. Schirripa, S. Cupini, C. Barbara, V. Safina, C. Granetto, E. Fea, L. Antonuzzo, C. Boni, G. Allegrini, S. Chiara, D. Amoroso, A. Bonetti, A. Falcone (2015)
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.Annals of oncology : official journal of the European Society for Medical Oncology, 26 4
-
A. Passardi, O. Nanni, D. Tassinari, D. Turci, L. Cavanna, A. Fontana, S. Ruscelli, C. Mucciarini, V. Lorusso, A. Ragazzini, G. Frassineti, D. Amadori (2015)
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial.Annals of oncology : official journal of the European Society for Medical Oncology, 26 6
-
G. Stathopoulos, C. Batziou, D. Trafalis, J. Koutantos, S. Batzios, J. Stathopoulos, J. Legakis, A. Armakolas (2010)
Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III StudyOncology, 78
-
I. Chau, F. Joulain, S. Iqbal, J. Bridgewater (2014)
A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRIBMC Cancer, 14
-
K. Pogue-Geile, G. Yothers, Y. Taniyama, Noriko Tanaka, P. Gavin, L. Colangelo, Nicole Blackmon, Corey Lipchik, Seong-Rim Kim, S. Sharif, C. Allegra, N. Petrelli, M. O’connell, N. Wolmark, S. Paik (2013)
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.Journal of the National Cancer Institute, 105 13
-
D. Le, J. Uram, Hao Wang, Bjarne Bartlett, H. Kemberling, A. Eyring, A. Skora, Brandon Luber, N. Azad, D. Laheru, B. Biedrzycki, R. Donehower, A. Zaheer, G. Fisher, T. Crocenzi, James Lee, Steven Duffy, R. Goldberg, A. Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R. Hruban, L. Wood, N. Cuka, D. Pardoll, N. Papadopoulos, K. Kinzler, Shibin Zhou, Toby Cornish, J. Taube, R. Anders, J. Eshleman, B. Vogelstein, L. Diaz (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.The New England journal of medicine, 372 26
-
J. Bennouna, J. Sastre, D. Arnold, P. Österlund, R. Greil, E. Cutsem, R. Moos, J. Viéitez, O. Bouché, C. Borg, C. Steffens, V. Alonso-Orduña, C. Schlichting, I. Reyes-Rivera, B. Bendahmane, T. André, S. Kubicka (2013)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.The Lancet. Oncology, 14 1
-
E. Cutsem, J. Tabernero, R. Lakomy, H. Prenen, J. Prausová, T. Macarulla, P. Ruff, G. Hazel, V. Moiseyenko, D. Ferry, J. Mckendrick, J. Polikoff, A. Tellier, R. Castan, C. Allegra (2012)
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 28
-
H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.The New England journal of medicine, 350 23
-
T. André, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, T. Hickish, C. Topham, M. Zaninelli, P. Clingan, J. Bridgewater, I. Tabah-Fisch, A. Gramont (2004)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.The New England journal of medicine, 350 23
-
A. Gramont, E. Cutsem, H. Schmoll, J. Tabernero, S. Clarke, M. Moore, D. Cunningham, T. Cartwright, J. Hecht, F. Rivera, S. Im, G. Bodoky, R. Salazar, F. Maindrault-Goebel, E. Shacham-Shmueli, E. Bajetta, M. Makrutzki, A. Shang, T. André, P. Hoff (2012)
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.The Lancet. Oncology, 13 12
- Publisher
- Springer Journals
- Copyright
- Copyright © 2017 by Springer-Verlag GmbH Austria
- Subject
- Medicine & Public Health; Oncology; Medicine/Public Health, general
- ISSN
- 1865-5041
- eISSN
- 1865-5076
- DOI
- 10.1007/s12254-017-0359-8
- Publisher site
- See Article on Publisher Site
Abstract
Angiogenesis is a very important step in the development of cancer. Several antiangiogenic biological agents have been studied during the past two decades for the treatment of colorectal cancer, both in adjuvant and metastatic settings. The first and most intensively studied is bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor. Since its approval in 2004, other antiangiogenic agents have been evaluated in clinical trials and some subsequently approved for the treatment of metastatic colorectal cancer such as aflibercept, ramucirumab, and regorafenib. In general, antiangiogenic agents show a modest efficacy in patients with metastatic colorectal cancer but not in the adjuvant setting. Also, there are no predictive biomarkers that could aid in selecting responsive patients. In this review we summarize the results of the completed large clinical trials investigating the efficacy of antiangiogenic therapies in colorectal cancer.
Journal
memo - Magazine of European Medical Oncology – Springer Journals
Published: Oct 25, 2017